Genedrive PLC (GDRG)

London
21.90
-0.75(-3.37%)
  • Volume:
    300,020
  • Bid/Ask:
    21.00/22.00
  • Day's Range:
    21.90 - 21.90

GDRG Overview

Prev. Close
22.25
Day's Range
21.9-21.9
Revenue
350K
Open
22.25
52 wk Range
21-163.42
EPS
-0.42
Volume
300,020
Market Cap
20.42M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
676,200
P/E Ratio
-
Beta
-1.83
1-Year Change
-82.45%
Shares Outstanding
91,753,018
Next Earnings Date
01 Dec 2021
What is your sentiment on Genedrive PLC?
or
Vote to see community's results!

Genedrive PLC News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyNeutralSellStrong SellStrong Sell
SummaryStrong BuyNeutralSellStrong SellStrong Sell

Genedrive PLC Company Profile

Genedrive PLC Company Profile

Genedrive Plc is a United Kingdom-based holding company engaged in molecular diagnostics business. The Company provides a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Its geographical segments include the United Kingdom, Europe, the United States of America and Asia. Genedrive is a small polymerase chain reaction (PCR) platform, which enables nucleic acid amplification and detection from various sample types, including plasma, sputum and buccal swabs. Genedrive system includes Genedrive hepatitis C virus (HCV) ID Kit for detection of Hepatitis C, and Genedrive IL28B ID Kit for the detection of Interleukin 28B genotyping status.

Read More
  • was a joke when prices were at 150p, its still a joke sitting at 28.5p. Pharma stocks was last years play. Likes of Iofina (IOFI) is where u wanna be in now!
    1
    • RNS released & no sales hence the price drop
      2
      • surprised the prof isn't on here playing down this surge
        2
        • Indian approvals granted for gdr . India must be really desperate....
          6
          • nice big gap to fill. put my bid low and fingers crossed
            1
            • So where is this NCYT bid for gdr then?
              4
              • Any approvals or sales yet? Or was it just all made up in the first place ? Maybe after the next placing CEO can get a nice lambo soon.
                3
                • David's fulfilled promises:22/05/20 "The Company aims to record first commercial sales in June" 22/10/20 "The Company is targeting end of the calendar year for completion of preliminary product evaluations with the release of the final CE marked system in Q1 2021". David says, 'Thanks for the £445,000 salary, bonuses and lavish expenses because I have delivered on every promise!". he also adds....."See you at the next placing!"
                  4
                  • How can the ceo justify paying himself £445,000 a year they when they only did £400,000 in sales in THE pandemic year
                    1
                    • The answer to your question is because he owns few shares in the company and using this climate as an opportnity to milk investors. I also suggest you don't even look at the expense accounts either. Me and my mates Silles and Paul Barnbrook all warned you, so we feel no empathy.What will happen:- The possibilty of failed approvals is a fairly strong possibilty.- You'll all discover the BC deal is tiny, overhyped and genuinely not needed as labs already have their own routines.- The next placing will occur in Summer/Autumn in the region of 5-10 mil GBP at significant discount- The SP may bounce to 100p and give false hope like it did before. Be warned,
                      2
                  • sinking faster than titanic
                    3
                    • joke company but next placing will cover extravagant salaries and expenses again for another year. We both preached it and we have now been vindicated.
                      3
                  • Once again proven correct. They can't sell anything after a year and two global waves. once vaccinations are complete it is game over here The BC deal is nothing but hot air as I said before. This company is bleeding cash thanks to the bod salary and will need a placing soon . facts are facts and ppl don't listen.
                    1
                    • So what happened to £600m takeover? Any sales or approvals yet?
                      1
                      • Danaher will eventually buy Genedrive, 400-600m .. around £7 per share, I won't be selling any until then.
                        1
                        • Any thoughts on when this would be 🤞
                          0
                        • Never
                          1
                        • What happened ?
                          1
                      • This is gonna drop below £1 next week if there is no news
                        8
                        • that didn't happen
                          1
                        • Drew Siebolol, what happened
                          0
                      • Looking v strong
                        1
                        • 4£ target end of March
                          6
                          • wee tree shake there
                            2
                            • Beckman Coulter distribution deal will be transformational for Genedrive
                              1
                              • Of course, it will be. just like when they announced it 6 months ago.   Keep pumping this and the sky is the limit.
                                1
                            • Looking like 300p+ next week is now in play.
                              2
                              • Giant Global pharma deal commencing next week
                                0
                                • Most overvalued covid stock. Dont even have any sales yet. CEO is rinsing the company with £455,000 salary
                                  2
                                  • Oliver WoodTitanic ?
                                    0
                                  • silles Illes Sometimes the stock market is not meant to make sense.   GDR in one year - zero sales.  Failed /delayed approvals. 8 week timeline for BC now gone to 6 months.   BC deal not even significant as the news was not even announced by them as they will be using GDR in small capacity trial rollout at first. BGF offloading huge chunks btw 50-60p. BOD grotesquely overpaid. Burning through cash like no tomorrow. Stuff on AIM generally now looking overvalued - look at RMS! Full ramp job done on Twitter and boards.   Do not underestimate the power of people together collectively!
                                    2
                                  • Pro Fessoryep, i cannot believe that I managed to sell out at 138 today.
                                    0
                                • they will go down
                                  0
                                  • 🤣
                                    0
                                  • Doesn't matter how bad a company is....never underestimate Twitter.... or GameStop type movements
                                    0
                                • Its a fickle old business this trading and investing game, but if you have done your due diligence, stick to your risk management plan and believe in your stock pick, then why would you care what some amateur says to try and influence you? Believe in your trading plan and ignore all the white noise. We are all at the mercy of things that are out of our control, may lady luck be with you all.
                                  2
                                  • Looking forward to seeing last years high (300p) surpassed over the coming month.
                                    0
                                    • Looks like Mid February for distribution to comence in the USA & Europe Great news for all shareholders.
                                      0
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.